Market open
Exact Sciences/$EXAS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Exact Sciences
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ticker
$EXAS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
6,550
Website
Exact Sciences Metrics
BasicAdvanced
$9.7B
-
-$1.17
1.27
-
Price and volume
Market cap
$9.7B
Beta
1.27
52-week high
$79.62
52-week low
$40.62
Average daily volume
2M
Financial strength
Current ratio
2.119
Quick ratio
1.783
Long term debt to equity
77.775
Total debt to equity
86.625
Interest coverage (TTM)
-8.98%
Management effectiveness
Return on assets (TTM)
-2.16%
Return on equity (TTM)
-6.76%
Valuation
Price to revenue (TTM)
3.563
Price to book
3.02
Price to tangible book (TTM)
-9.49
Price to free cash flow (TTM)
97.466
Growth
Revenue change (TTM)
11.91%
Earnings per share change (TTM)
-25.74%
3-year revenue growth (CAGR)
15.23%
3-year earnings per share growth (CAGR)
-37.30%
What the Analysts think about Exact Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Exact Sciences stock.
Exact Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Exact Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Exact Sciences News
AllArticlesVideos
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
Business Wire·1 week ago
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
Business Wire·3 weeks ago
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $9.7B as of February 11, 2025.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of February 11, 2025.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of February 11, 2025.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.